| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-12-10 | Korlym® (mifepristone) | metastatic triple negative breast cancer (TBNC) | 1-2 | Corcept Therapeutics (USA - CA) | Cancer - Oncology |
| 2016-12-09 | BI-505 | multiple myeloma | 2a | BioInvent (Sweden) | Cancer - Oncology |
| 2016-12-09 | VLA15 | Lyme borreliosis | 1 | Valneva (France- Austria) | Infectious diseases |
| 2016-12-09 | LEE011 (ribociclib) | postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer | 3 | Novartis (Switzerland) | Cancer - Oncology |
| 2016-12-09 | anti-Abeta antibody MABT5102A (crenezumab) | Alzheimer disease | 1 | Genentech, a member of Roche Group (USA - CA - Switzerland) | Neurodegenerative diseases |
| 2016-12-08 | Cimzia® (certolizumab pegol) | psoriasis | 3 | UCB (Belgium) | Autoimmune diseases - Dermatological diseases |
| 2016-12-08 | ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) | Alzheimer's disease | 2a | Anavex Life Sciences (USA - NY) | Neurodegenerative diseases |
| 2016-12-08 | poziotinib | lung cancer | preclinical | Spectrum Pharmaceuticals (USA - NV) | Cancer - Oncology |
| 2016-12-08 | abemaciclib (LY2835219) | breast cancer | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2016-12-08 | solanezumab | Alzheimer's disease | 3 | Eli Lilly (USA - IN) | Neurodegenerative diseases |
| 2016-12-08 | talazoparib (BMN 673) | metastatic breast cancer | 3 | Medivation (USA - CA), now Pfizer (USA - NY) | Cancer - Oncology |
| 2016-12-07 | NKR-2 (NKG2D CAR T-Cell) | acute myeloid leukemia, multiple myeloma | 1-2a | Celyad previously known as Cardio3 Biosciences (Belgium) | Cancer - Oncology |
| 2016-12-07 | seladelpar - MBX-8025 (2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate)l | primary biliary cholangitis | 2 | Cymabay Therapeutics (USA - CA) | Rare diseases - Hepatic diseases - Liver diseases |
| 2016-12-07 | brigatinib (AP26113) | non-small cell lung cancer (NSCLC) | 2 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-12-06 | OXi4503 (combretastatin A1-diphosphate or CA1P) | acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) | 1-2 | Mateon Therapeutics (USA - CA) | Cancer - Oncology |
| 2016-12-06 | ATIR101™ | blood cancer patients for whom a matched donor is not available for a standard transplantation procedure | 2 | Kiadis Pharma (The Netherlands) | Cancer - Oncology |
| 2016-12-05 | RNAdjuvant® Technology | preclinical | Curevac (Germany) | Cancer - Oncology | |
| 2016-12-05 | NOX-A12 (olaptesed pegol) with T cell and NK cell based therapies | preclinical | Noxxon Pharma (Germany) | Cancer - Oncology | |
| 2016-12-05 | anti-CD27 antibody | Aduro Biotech (USA - CA) Merck&Co (USA - NJ) | Cancer - Oncology | ||
| 2016-12-05 | ALN-CC5 | complement-mediated diseases, paroxysmal nocturnal hemoglobinuria (PNH) | 1-2 | Alnylam Pharmaceuticals (USA - MA) | Immunological diseases - Rare diseases |
